RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.08
−3.03%Oct 2, 2026, 11:00 UTC
Cartesian Therapeutics granted stock options to purchase an aggregate of 121,900 shares at $7.22 to four new employees as employment inducement awards on October 1, 2026.
Source:Sep 29, 2026, 11:30 UTC
Cartesian Therapeutics announced additional retreatment data for its Descartes-08 therapy showing deep and durable responses in patients with myasthenia gravis.
Source:Aug 6, 2026, 00:00 UTC
Cartesian Therapeutics reported Q2 2026 results with net income of $15.8 million and diluted EPS of $0.46, and cash and cash equivalents of $149.3 million at quarter end.
Aug 6, 2026, 00:00 UTC
Cartesian Therapeutics entered into a credit facility with total potential non-dilutive funding of up to $150 million, with a first funded tranche of $50 million.
Jun 9, 2026, 17:31 UTC
Cartesian Therapeutics entered into a strategic licensing agreement with WestGene Biopharma.
Source: